Health Canada clears two Moderna flu vaccines for adults 50+
Health Canada approved Moderna's mFLUSIVA and mCOFLU vaccines for adults 50+ on Nov 5, 2026. mFLUSIVA showed 26.6% efficacy in preventing flu cases, while mCOFLU was cleared based on antibody data. No launch date, price, or supply deals were announced. Moderna is valued at $96.4B.
How this was made
The 30-second read
Why it matters
Regulatory approval in a new market can unlock future sales and set precedent for other jurisdictions, but short‑term revenue impact is uncertain.
Market read
First Canadian approval of Moderna's flu vaccines; potential catalyst for stock movement and sector dynamics.
What to watch
mCOFLU cleared on immunogenicity only, which may limit payer adoption compared to efficacy‑based products.
Background
Moderna's mRNA flu vaccine portfolio expands with Health Canada approval, following earlier FDA and EU clearances.
Ticker impact
Health Canada authorized Moderna's mFLUSIVA and mCOFLU flu vaccines for adults 50+, a first-time approval in Canada.
likely upward pressure as market prices in regulatory clearance
Regulatory clearance is a material catalyst for a large-cap biotech; no launch terms disclosed yet, but approval alone can lift sentiment.
Market effects
Adds a new mRNA flu vaccine competitor for Sanofi and GSK, potentially reshaping the flu vaccine market.
Canada becomes the first market with both Moderna flu products, may influence other regulators.
Signals broader acceptance of mRNA flu vaccines, could affect global flu vaccine pricing and adoption.
Counterpoint
No launch date or pricing disclosed; market may overprice the approval without immediate revenue.
Key entities
- CompanyModerna Inc.
Developer of the approved mFLUSIVA and mCOFLU vaccines.
- RegulatorHealth Canada
Canadian health authority that granted the approvals.
